-
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable with U.S. Rep. Rich McCormick ATLANTA, Ga., August…
-
GeoVax Highlights Capabilities Amid Congo’s Expanding Ebola Outbreak
Company Prepared to Contribute Hemorrhagic Fever Vaccine Expertise and Candidates to Global Response Mpox/smallpox Remains Lead Infectious Disease Priority, with Broader MVA Portfolio…
-
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase
FDA Approval of Replimune’s Intratumoral Therapy in Combination with Checkpoint Inhibition Reinforces Growing Momentum Behind Tumor-Directed Approaches Designed to Enhance Anti-Tumor Immune Response…
-
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study
Manufacturing, Regulatory, Clinical and Preclinical Milestones Completed in Support of Scheduled Fourth Quarter 2026 Initiation of Pivotal Immune-Bridging Study ATLANTA, GA – August…
-
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio
Recent Third-Party Research Reinforces Scientific Rationale for Evaluating Broad-Spectrum Filovirus Preparedness Approaches ATLANTA, GA – August 3, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update
Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA, July 27, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Highlights Strategic Alignment of GEO-MVA with HHS/ASPR’s Five-Year Medical Countermeasure Preparedness Strategy
ASPR Report Reinforces National Priorities for Domestic Manufacturing, Platform Technologies, Strategic National Stockpile Modernization, and Pandemic Preparedness ATLANTA, GA – July 21, 2026…
-
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
Recent Federal Procurement Reinforces the Importance of Sustained Investment in Domestic Vaccine Manufacturing and Diversified Medical Countermeasures ATLANTA, GA – July 1, 2026 –…
-
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers
Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin® as a Potential Complement to Checkpoint Inhibitor Therapy ATLANTA, GA…
-
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses
Publication Highlights Potential for Intratumoral Gedeptin® Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity ATLANTA, GA – June 8, 2026 – GeoVax…
-
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape ATLANTA, GA…
-
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness
Largest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S.…